Salix Pharmaceuticals Ltd – Underwriting Agreements – BamSEC

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

SEC EDGAR

Underwriting Agreements Filter

from SC 13D 1 page Joint Filing Agreement

from 8-K 41 pages Salix Pharmaceuticals, Ltd. (A Delaware Corporation) $600,000,000 1.50% Convertible Senior Notes Due 2019 Purchase Agreement

from S-3ASR 41 pages Salix Pharmaceuticals, Ltd. (A Delaware Corporation) $[—] [—]% Convertible Senior Notes Due 2015 Underwriting Agreement

from 8-K 34 pages 5,500,000 Shares Salix Pharmaceuticals, Ltd. Common Stock Underwriting Agreement

from 8-K 45 pages $55,000,000 Aggregate Principal Amount Salix Pharmaceuticals, Ltd. 5.5% Convertible Senior Notes Due 2028 Purchase Agreement Dated August 18, 2008 Purchase Agreement

from SC 14D9 2 pages Your Board of Directors Unanimously Recommends That You Reject the Axcan Offer and Not Tender Your Shares. the Salix Board Believes That the Axcan Tender Offer Is Grossly Inadequate and Not in the Best Interests of Salix or Its Stockholders. the Factors Relied Upon by the Salix Board in Making Its Recommendation Include the Following

from S-3/A ~50 pages Underwriting Agreement

from 8-A12G ~50 pages Shareholder Protection Rights Agreement

from S-1/A ~50 pages Underwriting Agreement